INSM INSMED Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1104506 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY240.0%
TTM net income YoY48.8%
TTM EPS YoY54.6%
Revenue 3-yr CAGR75.6%
Net income 3-yr CAGR—
Margins
Gross margin84.4%
Operating margin-37.1%
Net margin-39.9%
FCF margin-41.3%
EBITDA margin-36.3%
Returns
ROE-72.5%
ROA-26.4%
ROIC (approx.)-43.8%
Asset turnover0.66x
Leverage & solvency
Liabilities / assets67.4%
Debt / equity0.76x
Current ratio2.86x
Interest coverage-6.93x
Cash quality & payout
Operating cash flow / net income0.98x
Accruals ratio-0.4%
Payout ratio—
Capex / revenue2.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $606.42M | $363.71M |
| Cost of revenue | $122.94M | $85.74M |
| Gross profit | $483.49M | $277.96M |
| R&D expense | $771.09M | $598.37M |
| SG&A expense | $701.17M | $461.12M |
| Operating income | -$1.25B | -$878.25M |
| Interest expense | $83.80M | $84.91M |
| Pretax income | -$1.27B | -$910.07M |
| Income tax | $5.03M | $3.71M |
| Net income | -$1.28B | -$913.77M |
| EBITDA | -$1.24B | -$872.29M |
| EPS (basic) | -6.42 | -5.57 |
| EPS (diluted) | -6.42 | -5.57 |
| Weighted avg. shares (diluted) | 199.01M | 164.04M |
| Balance sheet | ||
| Cash & equivalents | $510.44M | $555.03M |
| Short-term investments | $919.60M | $878.80M |
| Receivables | $140.86M | $52.01M |
| Inventory | $132.07M | $98.58M |
| Current assets | $1.79B | $1.62B |
| PP&E, net | $102.94M | $80.05M |
| Goodwill | $136.11M | $136.11M |
| Intangibles | $97.65M | $58.65M |
| Total assets | $2.26B | $2.03B |
| Current liabilities | $468.87M | $297.53M |
| Short-term debt | $0 | — |
| Long-term debt | $540.96M | $1.10B |
| Total debt | $540.96M | $1.10B |
| Total liabilities | $1.53B | $1.74B |
| Shareholders' equity | $738.98M | $285.38M |
| Net debt | $30.52M | $548.35M |
| Shares outstanding | 214.26M | 179.38M |
| Cash flow statement | ||
| Operating cash flow | -$935.01M | -$683.88M |
| Capital expenditure | $32.56M | $21.92M |
| Free cash flow | -$967.58M | -$705.80M |
| Investing cash flow | -$64.58M | -$583.17M |
| Financing cash flow | $954.07M | $1.34B |
| Depreciation & amortization | $10.45M | $5.96M |
| Stock-based compensation | $152.71M | $96.83M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.